CAJ | 학술논문

目的：探讨铁鳌合剂地拉罗斯及其联合顺铂对肺腺癌A549细胞增殖、凋亡的影响，为寻找肺癌有效的治疗途径提供依据。方法常规传代细胞培养方法培养肺腺癌细胞A549，以不同浓度的地拉罗斯、地拉罗斯联合顺铂干预细胞生长一定时间。在倒置显微镜下观察A549的生长抑制特征；MTT法检测细胞的增殖抑制状况；DAPI、AO/EB染色观察细胞凋亡的形态学变化；Annxin V-FITC/PI双染流式细胞术定量测定细胞凋亡状况。结果 A549细胞经不同浓度的药物作用一定时间以后，在倒置显微镜下可见随药物浓度和时间的增加，细胞数明显减少，细胞相互分散，贴壁细胞出现皱缩变小折光性差；MTT检测显示，细胞增殖抑制率随药物浓度的增加和作用时间的延长呈现上升趋势，即剂量效应关系及时间效应关系；DAPI、AO/EB染色法观察到细胞凋亡的形态学变化，即细胞发生染色质凝集，核固缩等典型的凋亡形态特征；流式细胞术检测显示，细胞的凋亡率随药物浓度的增加而升高，联合用药促细胞凋亡显著。结论铁鳌合剂地拉罗斯具有抗肺癌细胞A549增殖的能力，促进肿瘤细胞凋亡，其与顺铂联合可增强癌细胞耐受性，降低顺铂的用量及其不良反应。
목적：탐토철오합제지랍라사급기연합순박대폐선암A549세포증식、조망적영향，위심조폐암유효적치료도경제공의거。방법상규전대세포배양방법배양폐선암세포A549，이불동농도적지랍라사、지랍라사연합순박간예세포생장일정시간。재도치현미경하관찰A549적생장억제특정；MTT법검측세포적증식억제상황；DAPI、AO/EB염색관찰세포조망적형태학변화；Annxin V-FITC/PI쌍염류식세포술정량측정세포조망상황。결과 A549세포경불동농도적약물작용일정시간이후，재도치현미경하가견수약물농도화시간적증가，세포수명현감소，세포상호분산，첩벽세포출현추축변소절광성차；MTT검측현시，세포증식억제솔수약물농도적증가화작용시간적연장정현상승추세，즉제량효응관계급시간효응관계；DAPI、AO/EB염색법관찰도세포조망적형태학변화，즉세포발생염색질응집，핵고축등전형적조망형태특정；류식세포술검측현시，세포적조망솔수약물농도적증가이승고，연합용약촉세포조망현저。결론철오합제지랍라사구유항폐암세포A549증식적능력，촉진종류세포조망，기여순박연합가증강암세포내수성，강저순박적용량급기불량반응。
Objective To investigate the combination effect using iron chelators deferasirox and cisplatin on A549 cell proliferation and apoptosis and to provide evidences to explore an effective way to treat lung cancer. Methods Lung adeno?carcinoma cells were cultured by conventional way, with administration of different concentrations of deferasirox and cisplat?in. Cell growth inhibition was observed under an inverted microscope. Proliferation inhibition was evaluated by MTT assay. Morphological changes of cell apoptosis was detected using DAPI,AO/EB straning and flow cytometry. Results After a cer?tain time of incubation with different concentrations of the combined drugs,the cell number reduce significantly, which was counted under invert microscope. Cells were dispersed with each other and adherent cells appear shrunken and poor in re?fractivity. MTT assay showed that inhibition of cell proliferation was in a concentration-time-dependent manner. Chromatin condensation, nuclear condensation and other typical apoptotic morphology were detected after DAPI and AO/EB straning. Flow cytometry showed that apoptosis increased with rising drug concentration. So combination therapy was significantly pro-apoptotic. Conclusion Deferasirox has the ability to inhibit proliferation of A549 cells and can promote tumor cell apoptosis and enhances cancer cell tolerance when combined with cisplatin. It can also reduce the amount and toxicity of cis?platin. It provides a basis for finding an effective way to treat lung cancer.